Pfizer spins off new company with four rare disease therapies
The new company has been launched with a $103m Series A financing. Initially, SpringWorks will work on potential programs for four rare diseases – desmoid tumor, neurofibromatosis, hereditary xerocytosis
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.